Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies

For the purpose of exploring the development, pharmacology and clinical trial program related to dulaglutide, we conducted a nonsystematic review of dulaglutide, focusing on the AWARD (Assessment of Weekly Administration of LY2189265 [dulaglutide] in Diabetes Assessment) program of randomized, phase 3 studies. Dulaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist that causes a variety of antidiabetogenic actions by acting on the incretin system. Steady-state plasma concentrations of dulaglutide are achieved between 2 and 4 weeks following a once-weekly administration. The AWARD 1–6 studies were conducted in patients with different treatment needs, ranging from patients with mild diabetes who can be treated with diet management and exercise to patients for whom target glycemic control cannot be achieved with conventional insulin treatment. Changes in HbA1c from baseline to the primary endpoint assessment (primary efficacy outcome) with dulaglutide were generally dose-dependent and significantly greater than those of active comparators and placebos (AWARD 1–5) or non-inferior to the comparators (AWARD 6). The results of secondary outcome measures demonstrated that glycemic control attained with dulaglutide was sustained for long-term and that a greater proportion of patients treated with dulaglutide achieved a target HbA1c level of <7.0% compared with placebo and/or active comparators. Reduction in fasting serum glucose, glucagon levels and body weight after dulaglutide treatment were noted in most AWARD studies. Although treatment-emergent adverse events were common with dulaglutide, the incidence was similar to that of active comparators in most AWARD studies, and serious adverse events were generally infrequent, except in patients with more severe disease or with prolonged therapy. Hypoglycemic and immunogenic events were also infrequent.

In patients with type 2 diabetes, dulaglutide improves glycemic control and leads to clinically useful reduction in body weight in a range of treatment settings.

diabetes mellitus type 2, dulaglutide, glucagon-like peptide 1, hypoglycemic agents

1. Dedov I, Shestakova M, Benedetti MM, et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-95. doi: 10.1016/j.diabres.2016.02.010

2. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. – 2015. – Т. 18. – №1S. – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (7-th edition). Diabetes mellitus. 2015;18(1S):1-112. (in Russ.)] doi: 10.14341/DM20151S

3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007

4. Sidorenkov O, Nilssen O, Brenn T, et al. Prevalence of the metabolic syndrome and its components in Northwest Russia: The Arkhangelsk study. BMC Public Health. 2010;10:23. doi: 10.1186/1471-2458-10-23

5. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. doi: 10.1056/NEJMoa0802987

6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. doi: 10.1136/bmj.321.7258.405

7. American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care. 2012;35 Suppl 1:S11-63. doi: 10.2337/dc12-s011

8. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(Suppl 1):1-87. doi: 10.4158/EP15672.GLSUPPL

9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. Doi: 10.2337/dc14-2441

10. Adeghate E, Kalasz H. Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J. 2011;5(Suppl 2):78-81. doi: 10.2174/1874104501105010078

11. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68(15):2131-2162. doi: 10.2165/00003495-200868150-00005

12. Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab. 2007;21(4):535-553. doi: 10.1016/j.beem.2007.08.005

13. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3(5):365-372. doi: 10.1007/s11892-003-0079-9

14. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. doi: 10.1053/j.gastro.2007.03.054

15. Chia CW, Egan JM. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes. 2009;2:37-49. doi: 10.2147/DMSO.S4283

16. Schwartz SS, Epstein S, Corkey BE, et al. The time Is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care. 2016;39(2):179-186. doi: 10.2337/dc15-1585

17. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287-296. doi: 10.1002/dmrr.1080

18. Kuritzky L, Umpierrez G, Ekoe JM, et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126(6):60-72. doi: 10.3810/pgm.2014.10.2821

19. Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4(10):1015-1028. doi: 10.1002/emmm.201201379

20. Pabreja K, Mohd MA, Koole C, Wootten D, Furness SG. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol. 2014;171(5):1114-1128. doi: 10.1111/bph.12313

21. Madsbad S, Kielgast U, Asmar M, et al. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x

22. Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168-2176. doi: 10.2337/dc13-2759

23. Matfin G, Van Brunt K, Zimmermann AG, et al. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naive Patients With Type 2 Diabetes. J Diabetes Sci Technol. 2015;9(5):1071-1079. doi: 10.1177/1932296815583059

24. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23(1):119-124. doi: 10.1097/BOR.0b013e3283412fd4

25. Eli Lilly and Company. Dulaglutide (Trulicity) approved product information [Internet]. Updated 2015 Feb 19; cited 2017 Feb 27. Available from: http://uspl.lilly.com/trulicity/trulicity.html#pi

26. European Medicines Agency. Trulicity Summary of Product Characteristics [Internet]. Updated 2016 May 19; cited 2017 Feb 27. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf

27. ClinicalTrials.gov [Internet]. A study comparing dulaglutide with insulin glargine on glycemic control in participants with type 2 diabetes (T2D) and moderate or severe chronic kidney disease (CKD) (AWARD-7). (NCT01621178). Updated 2016 Jul 22; cited 2017 Feb 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01621178

28. Giorgino F, Benroubi M, Sun JH, et al. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-2249. doi: 10.2337/dc14-1625

29. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159-2167. doi: 10.2337/dc13-2760

30. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349-1357. doi: 10.1016/S0140-6736(14)60976-4

31. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149-2158. doi: 10.2337/dc13-2761

32. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057-2066. doi: 10.1016/S0140-6736(15)60936-9

33. Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849-858. doi: 10.1111/dom.12479

34. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104(1):1-52. doi: 10.1016/j.diabres.2012.10.001

35. Home P, Haddad J, Latif ZA, et al. Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries. Diabetes Ther. 2013;4(1):91-102. doi: 10.1007/s13300-013-0022-2

36. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481. doi: 10.1016/S0140-6736(08)61246-5

37. Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10):1260-1267. doi: 10.1111/j.1464-5491.2012.03745.x

38. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252-258. doi: 10.2337/dc11-1107

39. ClinicalTrials.gov [Internet]. A randomized, parallel-arm, double-blinded study comparing the effect of once-weekly dulaglutide with placebo in patients with type 2 diabetes mellitus on sulfonylurea therapy (AWARD-8: assessment of weekly administration of ly2189265 in diabetes – 8) (NCT01769378). Updated 2016 Jul 22; cited 2017 Feb 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01769378

40. ClinicalTrials.gov [Internet]. The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND). (NCT01394952). Updated 2016 Jul 21; cited 2017 Feb 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01394952

41. ClinicalTrials.gov [Internet]. A randomized, double-blind trial comparing the effect of dulaglutide 1.5 mg with placebo on glycemic control in patients with type 2 diabetes on basal insulin glargine. (NCT02152371) Updated 2016 Jul 22; cited 2017 Feb 27. Available from: https://clinicaltrials.gov/ct2/show/NCT02152371

42. Pozzilli P, Norwood P, Jodar E, et al. Improved glycemic control and weight loss with once weekly dulaglutide versus placebo, both added to titrated daily insulin glargine, in type 2 diabetes patients (AWARD-9). Diabetes. 2016;65(Suppl.1):A62. [abstract 237-OR] doi: 10.2337/db16-1-381